📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
RPG Life Sciences Clarifies Identical Q3 Results; API Division Spin-off to Subsidiary Underway
RPG Life Sciences clarified to the NSE that its standalone and consolidated financial results for Q3 FY26 are identical because its new subsidiary, RPG Active Pharma Limited, only commenced operations on January 6, 2026. The company reported a Q3 revenue of ₹18,003 Lakhs and a Profit After Tax of ₹2,213 Lakhs. Results were impacted by a one-time exceptional charge of ₹1,108 Lakhs due to the implementation of New Labour Codes. The internal reorganization to transfer the API division is expected to be completed by February 2026 to streamline business focus.
Key Highlights
Q3 FY26 Revenue from operations stood at ₹18,003 Lakhs, a growth from ₹17,271 Lakhs in the previous year's corresponding quarter.
Net Profit for the quarter was ₹2,213 Lakhs, after accounting for a ₹1,108 Lakhs exceptional expense for New Labour Code obligations.
The company is transferring its API division to a new wholly-owned subsidiary, RPG Active Pharma Limited, incorporated on December 24, 2025.
Insurance recovery for the January 2025 fire incident is progressing, with ₹2,050 Lakhs received against a total loss of ₹2,295 Lakhs.
Nine-month FY26 Revenue reached ₹53,063 Lakhs with a Net Profit of ₹8,527 Lakhs.
💼 Action for Investors
Investors should monitor the completion of the API division transfer and its impact on operational efficiency. The exceptional hit from the New Labour Code is a one-time regulatory adjustment and does not reflect on core business performance.
RPG Life Sciences Q3 FY26: Revenue Up 4.2% to ₹180 Cr, PAT Declines 20% YoY
RPG Life Sciences reported a modest 4.2% YoY revenue growth in Q3 FY26, reaching ₹180 crore, primarily driven by a 12.5% growth in its Domestic Formulations segment. However, profitability faced significant pressure as PAT declined 20% YoY to ₹27.9 crore and EBITDA margins contracted from 30.4% to 24.0%. The API segment was particularly weak, with a 19.4% revenue decline in 9M FY26 due to a fire incident at a manufacturing block. Despite these headwinds, the company remains debt-free and is proceeding with a ₹140 crore capex plan for global expansion.
Key Highlights
Q3 FY26 Revenue grew 4.2% YoY to ₹180 Cr, while 9M FY26 Revenue rose 4.0% to ₹530.6 Cr.
PAT for Q3 FY26 dropped 20% YoY to ₹27.9 Cr, with EBITDA margins contracting to 24.0% from 30.4%.
Domestic Formulations, contributing 70% of sales, grew 12.5% in 9M FY26, outperforming market growth.
API segment revenue fell 19.4% in 9M FY26, impacted by a fire incident in one of the manufacturing blocks.
The company maintains a debt-free balance sheet and is investing ₹140 Cr in capex to expand its international footprint.
💼 Action for Investors
The significant margin contraction and the fire-related disruption in the API segment are short-term negatives. Investors should watch for the recovery of API operations and the impact of the ₹140 crore capex on future growth before increasing exposure.
RPG Life Sciences Q3 FY26: Revenue up 4% to ₹180 Cr; PAT drops 20% on API Segment Fire Disruption
RPG Life Sciences reported a modest 4.2% YoY revenue growth to ₹180.0 crore for Q3 FY26, but profitability faced significant pressure. PAT declined by 19.8% to ₹27.9 crore, and EBITDA margins contracted from 30.4% to 24.0% YoY. The performance was primarily dragged down by the API segment, which saw a 19.4% revenue decline in 9M FY26 due to a fire incident at a manufacturing block. Despite this, the Domestic Formulations business grew 8.9% and the company remains debt-free with a ₹140 crore capex plan for global expansion.
Key Highlights
Q3 FY26 Revenue grew 4.2% YoY to ₹180.0 Cr, while 9M FY26 Revenue reached ₹530.6 Cr (+4% YoY).
PAT for Q3 FY26 fell 19.8% to ₹27.9 Cr, and EBITDA declined 17.7% to ₹43.2 Cr.
API segment revenue for 9M FY26 dropped 19.4% to ₹61.7 Cr following a fire incident in a manufacturing block.
Domestic Formulations (71% of total sales) grew 8.9% in 9M FY26, reaching ₹364.6 Cr.
Company remains debt-free and is executing a ₹140 Cr capex for international market expansion.
💼 Action for Investors
Investors should monitor the timeline for the full restoration of the API manufacturing block and the impact of the ₹140 crore capex on future growth. While the domestic business remains a strong anchor, the short-term margin compression warrants a cautious approach until API operations normalize.
RPG Life Sciences Q3 FY26 Revenue Up 4.2% Y-o-Y to Rs 180 Cr; EBITDA Margin at 24%
RPG Life Sciences reported a steady performance for Q3 FY26 with revenue growing 4.2% Y-o-Y to Rs 180.0 crores. The company maintained a healthy EBITDA margin of 24.0%, reflecting operational efficiency despite a marginal Q-o-Q revenue dip from Rs 181.7 crores. Notably, the Domestic Formulations segment grew by 11.8% in the first nine months of FY26, significantly outperforming the Indian Pharmaceutical Market (IPM) growth of 8.2%. Overall 9M FY26 revenue reached Rs 530.6 crores, up from Rs 510.3 crores in the previous year.
Key Highlights
Q3 FY26 Revenue grew 4.2% Y-o-Y to Rs 180.0 crores vs Rs 172.7 crores in Q3 FY25
EBITDA margin remained robust at 24.0% for the quarter
Domestic Formulations business grew 11.8% in 9M FY26, outperforming the IPM growth of 8.2%
9M FY26 total revenue reached Rs 530.6 crores, a 4.0% increase Y-o-Y
Q-o-Q revenue saw a slight decline from Rs 181.7 crores to Rs 180.0 crores
💼 Action for Investors
Investors should take note of the company's consistent ability to outperform the domestic pharma market growth and maintain high margins. The stock remains a solid mid-cap pharma play focused on branded formulations and operational efficiency.
RPG Life Sciences Approves Q3 FY26 Unaudited Financial Results
RPG Life Sciences Limited has officially approved its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board meeting, held on January 27, 2026, concluded with the submission of these results along with the Statutory Auditor's Limited Review Report. While the specific profit and revenue figures were not detailed in the cover letter, the filing confirms compliance with SEBI Listing Obligations. Investors should now examine the full financial tables to evaluate the company's performance trajectory for the fiscal year.
Key Highlights
Board approved unaudited financial results for the quarter ended December 31, 2025
Consolidated and standalone results for the nine-month period were submitted to exchanges
The board meeting lasted three and a half hours, concluding at 6:30 p.m.
Statutory auditors have provided a Limited Review Report for the period
💼 Action for Investors
Investors should review the detailed profit and loss statements to assess margin trends and revenue growth compared to the previous year. Monitor the stock's price action in the coming sessions for the market's reaction to the specific earnings data.
RPG Life Sciences Board Approves Q3 FY26 Unaudited Financial Results
RPG Life Sciences Limited held its board meeting on January 27, 2026, to approve the unaudited financial results for the quarter and nine months ended December 31, 2025. The board reviewed both standalone and consolidated financial statements, ensuring compliance with SEBI Listing Obligations. The meeting, which lasted three and a half hours, concluded with the submission of the results and the statutory auditor's Limited Review Report. This is a routine but critical regulatory update for the third quarter of the 2025-26 fiscal year.
Key Highlights
Board approved unaudited standalone and consolidated financial results for Q3 FY26.
Financial results cover the nine-month period ending December 31, 2025.
Statutory Auditors issued a Limited Review Report on the financial statements.
The board meeting was conducted from 03:00 p.m. to 06:30 p.m. on January 27, 2026.
💼 Action for Investors
Investors should examine the detailed financial tables and auditor's report once released to evaluate the company's revenue growth and margin stability. Compare the Q3 performance against year-on-year benchmarks to assess long-term value.
RPG Life Sciences Incorporates Wholly Owned Subsidiary RPG Active Pharma Limited
RPG Life Sciences Limited has officially incorporated a new wholly owned subsidiary named RPG Active Pharma Limited on December 24, 2025. This move follows the company's prior intimation on December 15, 2025, regarding the strategic intent to form this entity. The new subsidiary is registered under CIN U21001MH2025PLC464091 and is expected to focus on specialized pharmaceutical operations. This structural expansion indicates a potential focus on the Active Pharmaceutical Ingredients (API) segment or a dedicated business vertical to drive future growth.
Key Highlights
Incorporated a 100% wholly owned subsidiary named RPG Active Pharma Limited on December 24, 2025
The new entity is registered under Corporate Identification Number (CIN) U21001MH2025PLC464091
The incorporation follows a prior regulatory intimation dated December 15, 2025
The move aligns with the company's long-term growth strategy within the pharmaceutical sector
💼 Action for Investors
Investors should monitor future announcements regarding the specific business objectives and capital expenditure plans for this new subsidiary. This expansion could potentially enhance the company's manufacturing capabilities and market reach in the API segment.
RPGLIFE appoints Amol Lone as CFO, to incorporate RPG Active Pharma
RPG Life Sciences has appointed Mr. Amol Lone as the Chief Financial Officer (CFO) effective December 15, 2025. The company will also incorporate a wholly-owned subsidiary, "RPG Active Pharma Limited," for manufacturing and marketing active pharmaceutical ingredients (API). RPGLIFE plans to transfer its existing API business, which contributed ₹90.24 crores (13.8%) to FY25 turnover, to the new subsidiary. An investment of up to ₹105 crore will be made in the WOS in one or more tranches.
Key Highlights
Amol Lone appointed as CFO effective December 15, 2025
API business contributed ₹90.24 crores to FY25 turnover
API business net worth as on March 31, 2025 was ₹90.61 crores
Investment of up to ₹105 crore in the new WOS
Consideration for API business transfer expected to be approximately ₹50 crore
💼 Action for Investors
Investors should monitor the progress of the API business transfer and the performance of the new subsidiary, RPG Active Pharma Limited. Keep an eye on how the ₹105 crore investment impacts the company's growth and profitability.
RPGLIFE Board approves API business transfer to new wholly-owned subsidiary
RPG Life Sciences' board approved the transfer of its API business, which contributed ₹90.24 crore (13.8%) to FY25 turnover, to a new wholly-owned subsidiary (WOS). The net worth of the API business as of March 31, 2025, was ₹90.61 crore, representing 17.1% of the company's total net worth. The company will invest up to ₹105 crore in the WOS in tranches. The consideration for the transfer is expected to be approximately ₹50 crore.
Key Highlights
API business contributed ₹90.24 crore to FY25 turnover (13.8%).
Net worth of API business was ₹90.61 crore as of March 31, 2025 (17.1% of total).
Investment of up to ₹105 crore in the WOS.
Consideration for API business transfer expected to be approximately ₹50 crore.
💼 Action for Investors
Investors should monitor the progress of the API business transfer and the performance of the new subsidiary. Keep an eye on how the ₹105 crore investment impacts the company's growth.